Immunohistochemical assessment of hormone receptor status of breast carcinoma : Interobserver variation of the quick score

Mudduwa, Lakmini; Liyanage, Thusharie

doi:10.4103/0019-5359.49078

Cited by 8 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They were photographed using an Olympus® C-5050 digital camera connected to an Olympus® BX-50 microscope and QuickPHOTO Pro software. The histomorphological analysis determined the existence, proportion and signal strength of TFF protein expression in individual samples using the Modified Quick Score (Q) method of immunohistochemical staining ( 35 , 36 ). Modified Quick Score method is presented in Table 2.…”

Section: Methodsmentioning

confidence: 99%

Differential Expression of TFF Genes and Proteins in Breast Tumors

Levak

Mihalj

Koprivčić

et al. 2018

ACC

View full text Add to dashboard Cite

SUMMARY – The objective of this study was to determine differential expression of TFF1, TFF2 and TFF3 genes and proteins in breast tumor subtypes. In addition, we investigated the correlation between TFF genes within tumor subgroups, and TFF genes with clinical and pathologic characteristics of the tumor. Study group included 122 patients with surgically removed breast tumors. Samples were investigated using qRT-PCR and immunohistochemistry. TFF1 and TFF3 genes and proteins were expressed in breast tumors, while the levels of TFF2 gene and protein expression were very low or undetectable. TFF1 was significantly more expressed in benign tumors, while TFF3 was more expressed in malignant tumors. Gene and protein expression of both TFF1 and TFF3 was greater in lymph node-negative tumors, hormone positive tumors, tumors with moderate levels of Ki67 expression, and in grade II tumors. A strong positive correlation was found between TFF1 and TFF3 genes, and the expression of both negatively correlated with Ki67 and the level of tumor histologic differentiation. Our results suggest that TFF1 and TFF3, but not TFF2, may have a role in breast tumor pathogenesis and could be used in the assessment of tumor differentiation and malignancy.

show abstract

Section: Methodsmentioning

confidence: 99%

Differential Expression of TFF Genes and Proteins in Breast Tumors

Levak

Mihalj

Koprivčić

et al. 2018

ACC

View full text Add to dashboard Cite

show abstract

“…It is subject to intra-laboratory and inter-laboratory variability. For instance, the inter-observer agreement in scoring hormone receptor status by IHC can vary from moderate to almost perfect (k = 0.78 to 0.85 for ER status, k = 0.71 to 0.72 for PR status [ 1 ] [ 2 ]). The discordance rate is mainly due to differences of interpretation of the specificity of staining and the histological structures after immunostaining.…”

Section: Introductionmentioning

confidence: 99%

Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay

et al. 2016

View full text Add to dashboard Cite

BackgroundHormone receptor status and HER2 status are of critical interest in determining the prognosis of breast cancer patients. Their status is routinely assessed by immunohistochemistry (IHC). However, it is subject to intra-laboratory and inter-laboratory variability. The aim of our study was to compare the estrogen receptor, progesterone receptor and HER2 status as determined by the MapQuant™ test to the routine immuno-histochemical tests in early stage invasive breast cancer in a large comprehensive cancer center.Patients and MethodsWe retrospectively studied 163 invasive early-stage breast carcinoma with standard IHC status. The genomic status was determined using the MapQuant™ test providing the genomic grade index.ResultsWe found only 4 tumours out of 161 (2.5%) with discrepant IHC and genomic results concerning ER status. The concordance rate between the two methods was 97.5% and the Cohen’s Kappa coefficient was 0.89.Comparison between the MapQuant™ PR status and the PR IHC status gave more discrepancies. The concordance rate between the two methods was 91.4% and the Cohen’s Kappa coefficient was 0.74.The HER2 MapQuant™ test was classified as « undetermined » in 2 out of 163 cases (1.2%). One HER2 IHC-negative tumour was found positive with a high HER2 MapQuant™ genomic score. The concordance rate between the two methods was 99.3% and the Cohen’s Kappa coefficient was 0.86.ConclusionOur results show that the MapQuant™ assay, based on mRNA expression assay, provides an objective and quantitative assessment of Estrogen receptor, Progesterone receptor and HER2 status in invasive breast cancer.

show abstract

“…Panels evaluating biomarkers have published scoring and handling recommendations 1,10,[16][17][18] all aiming toward standardization of diagnostic evaluation. Nevertheless, both interobserver [19][20][21][22][23][24][25] and intraobserver variation [25][26][27][28][29] have been demonstrated to have an undesired role in patient diagnosis. Immunohistochemistry relies heavily on the skill set of the trained pathologist.…”

mentioning

confidence: 99%

A novel quantitative immunohistochemistry method for precise protein measurements directly in formalin-fixed, paraffin-embedded specimens: analytical performance measuring HER2

Jensen

Krusenstjerna-Hafstrøm

Lohse

et al. 2017

Modern Pathology

View full text Add to dashboard Cite

In clinical routine pathology today, detection of protein in intact formalin-fixed, paraffin-embedded tissue is limited to immunohistochemistry, which is semi-quantitative. This study presents a new and reliable quantitative immunohistochemistry method, qIHC, based on a novel amplification system that enables quantification of protein directly in formalin-fixed, paraffin-embedded tissue by counting of dots. The qIHC technology can be combined with standard immunohistochemistry, and assessed using standard bright-field microscopy or image analysis. The objective was to study analytical performance of the qIHC method. qIHC was tested under requirements for an analytical quantitative test, and compared with ELISA and flow cytometry for quantitative protein measurements. Human epidermal growth factor receptor 2 (HER2) protein expression was measured in five different cell lines with HER2 expression from undetectable with immunohistochemistry to strong positive staining (IHC 3+). Repeatability, reproducibility, robustness, linearity, dynamic range, sensitivity, and quantification limits were evaluated. Reproducibility and robustness were assessed in a setup to resemble daily work in a laboratory using a commercial immunohistochemistry platform. In addition, qIHC was correlated to standard HER2 immunohistochemistry in 44 breast cancer specimens. For all evaluated parameters, qIHC performance was either comparable or better than the reference methods. Furthermore, qIHC has a lower limit of detection than both immunohistochemistry and the ELISA reference method, and demonstrated ability to measure HER2 accurately and precise within a large dynamic range. In conclusion, the results show that qIHC provides a sensitive, quantitative, accurate, and robust assay for measurement of protein expression in formalin-fixed, paraffin-embedded cell lines, and tissue.

show abstract

Immunohistochemical assessment of hormone receptor status of breast carcinoma : Interobserver variation of the quick score

Cited by 8 publications

References 8 publications

Differential Expression of TFF Genes and Proteins in Breast Tumors

Differential Expression of TFF Genes and Proteins in Breast Tumors

Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay

A novel quantitative immunohistochemistry method for precise protein measurements directly in formalin-fixed, paraffin-embedded specimens: analytical performance measuring HER2

Contact Info

Product

Resources

About